What Should I Look For When Choosing a Food Microbiology Lab in Canada?

Key Takeaways

Your lab contract renewal is one of the highest‑impact food safety decisions you make on a fixed cycle, and it should be treated as a structured risk review, not an automatic rollover.
ISO/IEC 17025 accreditation from an SCC‑recognized body is a baseline requirement, but only if the scope covers the specific tests, methods, and matrices your Preventive Control Plan relies on.
Method choice and validation matter as much as the reported result; alignment with Health Canada HPB, ISO, AOAC, and FDA BAM methods determines whether COAs stand up in CFIA, GFSI, and customer audits.
The lab’s real value shows when something goes wrong, such as EMP exceedances, regulatory inquiries, or shelf‑life failures, where technical support and documentation quality become as important as raw test capacity.
Price alone is a poor selection criterion; cheap or poorly scoped testing quietly increases recall exposure, audit findings, and downtime in ways that far outweigh savings on per‑test fees.
A structured renewal framework, including accreditation checks, performance review, capability alignment, and contract verification, turns lab choice into a defensible governance decision instead of an administrative habit.

Article at a Glance

For Canadian food manufacturers, the microbiology lab is not just a vendor. It is the evidentiary backbone of the food safety program. Every COA, EMP trend, and validation report you file with your Preventive Control Plan depends on the competence, methods, and governance of that external partner. Treating lab selection as a subscription renewal erodes that backbone over time.

This article walks QA directors, plant managers, and executives through a practical contract renewal checklist that reflects CFIA, SFCR, Health Canada, GFSI, and export expectations. It explains how to verify ISO/IEC 17025 accreditation scope, evaluate method portfolios, test the lab’s fit for your products and risk profile, and frame cost discussions in terms of risk and ROI rather than unit price.

You will also find a structured renewal framework, concrete EMP partnership questions, scenario examples from different plant profiles, and leadership‑grade FAQs. The goal is not to turn you into a laboratory auditor, but to give you a clear, defensible way to decide whether your current lab should remain a core part of your food safety system for the next contract cycle.

The Wrong Lab Can Cost You More Than Money

Why lab choice belongs on the executive risk agenda

Most manufacturers would not tolerate a supplier whose quality system had not been assessed in years, yet many plants renew lab contracts with less scrutiny than they apply to stretch wrap or corrugated. The lab is not a commodity input. It generates the data that CFIA inspectors, GFSI auditors, retail customers, and, in serious incidents, legal teams will examine line by line.

When regulators review your Preventive Control Plan, they look beyond whether testing occurred. They ask whether it was carried out using recognized methods, by a competent and accredited lab, on a sampling plan that reflects the true risk profile of your products and processes. COAs from a lab that cannot show method validation, proficiency testing participation, or appropriate accreditation scope quickly become findings, and in a recall or enforcement case they become liabilities.

A single weak point in the chain can amplify costs. An environmental positive from a poorly designed EMP, relying on questionable methods, creates ambiguity about whether a result reflects real contamination or a testing artifact. Ambiguous data slows corrective actions, complicates communication with regulators and customers, and keeps lines idle longer. These costs rarely appear in procurement spreadsheets, yet they are the ones that define whether a lab choice was truly “cheaper.”

For these reasons, lab selection and renewal deserve executive visibility. The financial and regulatory consequences of a poor lab relationship affect the entire organization, not just QA. Treating renewal as a structured risk review, with documented criteria and sign‑off from QA, operations, and finance, is a governance decision, not a courtesy to your lab.

Accreditation and Regulatory Defensibility

Why ISO/IEC 17025 from SCC is a baseline

ISO/IEC 17025 is the international standard for testing and calibration laboratory competence. In Canada, labs are accredited to this standard by the Standards Council of Canada and recognized accreditation bodies. For food microbiology, that accreditation signals independent assessment of management systems, technical competence, equipment calibration, method validation, staff qualifications, and participation in proficiency testing.

Accreditation is not a marketing badge. It is the shortest way to demonstrate to CFIA, Health Canada, GFSI auditors, and major retailers that your lab operates under a quality system that has been objectively assessed. For any testing that feeds into PCP verification, EMP pathogen monitoring, validation studies, or customer‑facing documentation, ISO/IEC 17025 accreditation from an SCC‑recognized body should be treated as non‑negotiable.

What ISO/IEC 17025 actually means for your program

Accreditation confirms that the lab has been evaluated against ISO/IEC 17025 for specific tests and matrices. It does not mean every test on the lab’s menu is accredited, nor that every matrix they accept is covered. This distinction is where many programs drift into risk. A lab can be legitimately accredited and still perform a significant amount of work outside its accredited scope, unless clients ask precise questions.

Within scope, methods must be validated for the matrices they are applied to, with documented uncertainty, detection limits, and reproducibility. Staff competence is monitored through training records, proficiency testing, and internal QC. When this system functions correctly, each COA is tied back to a defensible set of methods, records, and quality checks, not just a number on a page. You should see specific methods referenced, accreditation identifiers, and clear identification of matrices. Inconsistent or vague COAs are an early warning sign.

How to verify accreditation and scope

Verifying accreditation is straightforward and should be part of every renewal:

Retrieve the lab’s current ISO/IEC 17025 certificate and scope from the SCC directory or the accreditation body.
Map the scope against your active test list by analyte, method, and matrix.
Confirm that pathogen tests, key EMP methods, and shelf‑life indicators are within scope for the specific product categories you manufacture.
Document this mapping as part of your supplier qualification file.

This exercise typically takes under an hour and provides clear evidence of due diligence if CFIA or a GFSI auditor asks how you qualified your lab. It also flushes out a common failure mode: tests running outside scope simply because no one has looked closely since the relationship began.

Common gaps even accredited labs can create

Accreditation is necessary but not sufficient. Gaps that cause trouble in audits and investigations tend to fall into three patterns:

Tests run outside accredited scope without clear disclosure.
Methods used on matrices for which they were never validated.
COAs that do not clearly tie results to an accredited method or matrix.

A second group of gaps involves proficiency testing. Accreditation requires participation, but frequency, analyte coverage, and performance vary. During qualification and renewal reviews, ask explicitly which proficiency schemes the lab participates in for your key analytes, how often, and how results are reviewed internally. The answers will tell you more about real‑world data quality than any sales brochure.

Methods, Compendia, and Data That Stands Up in Audits

Why method choice is a strategic decision

Once you have confirmed accreditation, the next screen is method strategy. For Canadian food manufacturers, this means understanding how Health Canada HPB methods, ISO standards, AOAC Official Methods, and FDA BAM procedures fit together for your products and markets.

In a CFIA inspection, customer technical audit, or export review, method choice can determine whether data are accepted at face value or questioned. A pathogen result generated using a non‑recognized or poorly validated method may force you into re‑testing, delay decision‑making, or weaken your position when explaining how you verified control of a hazard.

Aligning methods with CFIA, Health Canada, and export expectations

SFCR and CFIA inspection programs do not prescribe a single method for every test, but they expect that methods used for verification and validation are scientifically valid, fit for purpose, and aligned with recognized compendia. Health Canada’s HPB methods are the primary Canadian reference, often harmonized with ISO and AOAC. For exports, FDA BAM and specific ISO references can become equally important.

Practical steps for method alignment during lab selection and renewal:

Request a method list that covers all tests you submit, with references to HPB, ISO, AOAC, or FDA BAM where applicable.
Confirm that methods used for PCP verification, EMP pathogen detection, and validation samples trace back to recognized procedures.
Ask how the lab manages method changes, including communication, re‑validation, and documentation to support your PCP.

You should be able to see, on paper, which method is used for each critical test and why it is acceptable for your regulatory and customer context.

Rapid methods versus reference methods

Rapid methods such as PCR assays and automated immunoassays have become standard for microbiology because they compress turnaround time. Their regulatory acceptability depends on three factors:

Recognition status (for example AOAC Performance Tested Methods or Official Method designation).
Matrix validation that matches the products you actually manufacture.
Confirmation protocols for presumptive positives through reference methods.

For routine monitoring and trend analysis, validated rapid methods are usually appropriate. For high‑stakes investigations, regulatory submissions, and enforcement scenarios, reference methods still carry more weight.

Questions to settle before renewal or transition:

Which analyses are run by rapid methods, and what validation exists for your matrices?
How are rapid method results confirmed, reported, and documented on COAs?
Does the lab maintain capacity to run reference methods when needed, or would you have to move samples elsewhere during an incident?

Documenting method equivalence in your PCP, even in short form, closes a gap that inspectors notice quickly when it is missing. Your lab should be willing and able to provide supporting documents that make that rationale easy to add to your program.

Product Category Expertise and Specialized Studies

Why matrix and process familiarity matter

Accreditation and method alignment define a technical floor. The real differentiation appears when your program moves beyond routine indicator and pathogen testing into environmental monitoring design, shelf‑life work, and validation. At that point, the question shifts from “Can they run the test?” to “Do they understand the product and process well enough to help us ask the right questions?”

A lab whose portfolio is dominated by dairy behaves differently from one that has deep experience with RTE meats, low‑moisture snacks, or high‑acid foods. Those differences matter when you are troubleshooting sporadic spoilage or interpreting a puzzling EMP pattern.

Assessing fit for your products and processes

When you qualify or renew a lab, ask concrete questions about your own categories:

How many clients do you serve in our product category and risk profile?
What types of EMP investigations, challenge studies, or validation projects have you supported in that space?
What recurring issues do you see for plants like ours, and how have you helped them resolve those issues?

Beyond product category, probe process familiarity. A lab that understands your thermal steps, pH and water activity controls, packaging atmosphere, and post‑lethality exposure can offer more nuanced interpretation and smarter sampling recommendations than one that treats every submission in isolation.

When you need a specialized validation partner

Routine labs are not always equipped to design and run formal validation studies. Kill‑step validation, pathogen challenge testing for shelf‑life claims, and process lethality work for submissions to CFIA, Health Canada, or FDA require deeper microbiological and statistical expertise.

Signs that you should engage a specialized validation partner:

Your products are RTE, high‑risk, or export‑oriented and make explicit safety claims.
Regulators or customers are asking for formal validation reports, not only historical COAs.
Your current lab hesitates or cannot provide detailed protocols and sample reports for similar work.

Many manufacturers successfully use a hybrid model: a primary lab for routine testing and an expert partner for validation studies. The key is clear division of responsibilities, coordination on methods, and unambiguous documentation so nothing falls between those two roles.

Documentation that withstands scrutiny

Ask any lab proposing validation work to provide sample reports. At minimum, a defensible validation report should include:

A clearly defined objective and scope.
Defined target and surrogate organisms with rationale.
Detailed protocols, including inoculation, conditions, sampling plan, and controls.
Raw data tables with traceability.
Appropriate analysis and interpretation that link back to process parameters.
Stated limitations and triggers for re‑validation.

If your current lab’s documentation does not meet this standard, that gap should be addressed before you rely on their work to support regulatory or customer filings.

Service Model, Turnaround, and Operational Fit

Turnaround time and capacity

Technical excellence does not matter much if results arrive too late to support release decisions. Indicator panels for routine food microbiology are typically delivered within two to three business days, and pathogen screens within three to five, depending on method choice. The operational question is whether your lab can maintain these windows under real load.

During renewal, review actual versus committed turnaround performance for:

Hold‑and‑release samples.
Routine EMP samples.
Rush or incident‑related submissions.

A small number of well‑understood misses with clear explanations is manageable. A pattern of quietly slipping deadlines is not. Turnaround expectations should be reflected in the contract as specific service levels, with clear definitions for routine versus rush work and any associated premiums.

Weekend and after‑hours expectations

Few plants operate on a strict weekday schedule. If you run weekends or operate on tight shipping timelines, clarify:

Does the lab receive and process weekend samples, or do they queue until Monday?
Is there a defined after‑hours escalation path for presumptive positives or urgent interpretation needs?
Who is authorized to make time‑sensitive decisions on their side, and how can your team reach them?

These details are easy to overlook when the relationship is calm and very visible when something goes wrong.

Logistics, chain of custody, and data access

Sample integrity is foundational. A credible lab should be able to explain and document:

Chain‑of‑custody controls from receipt through disposal.
Temperature and condition checks on arrival.
Handling rules for compromised samples and how clients are notified.

From a governance perspective, LIMS and data access now matter as much as courier routes. A modern lab should offer:

A secure portal with real‑time sample status and result access.
Easy export of data in formats your systems can use.
Clear data retention and retrieval commitments that align with your regulatory obligations and shelf‑life windows.

Your contract should also address data portability in case of ownership changes or lab closure, so historical testing records remain accessible as a long‑term asset of your program.

Technical Support and Partnership Approach

From sample processing to scientific partnership

The simplest way to distinguish a commodity vendor from a technical partner is to examine what happens between sample receipt and COA delivery, and what support is available when a result does not fit the pattern. A transactional lab sends numbers. A partner helps you understand what those numbers mean for your process and your risk.

You should expect a credible food microbiology lab to:

Provide access to technical staff who can discuss results and trends with your QA team.
Help refine sampling plans when EMP data are noisy or non‑actionable.
Support document preparation and method explanations during audits or regulatory inquiries.
Collaborate on study design for targeted investigations, not just run tests you specify.

When qualifying or renewing, ask for concrete examples of how they have helped clients in similar categories work through confusing trends or positive findings. The specificity of their answers will tell you whether they truly operate as partners.

EMP design and PCP verification support

Environmental monitoring is one of the clearest places where lab expertise can improve program effectiveness. A strong partner can help you:

Review zone maps and sampling site choices for blind spots.
Choose indicator organisms that are predictive for your process and environment.
Adjust sampling frequencies based on risk, history, and regulatory expectations.
Plan follow‑up sampling and documentation after an exceedance.

This does not shift ownership of the EMP away from your plant. It supplements your internal knowledge with external expertise and gives you a documented scientific rationale that holds up under CFIA and GFSI review.

EMP partnership capability checklist

Use the table below when assessing EMP support during lab qualification or renewal.

EMP Partnership Capability Assessment

Capability area	Questions to ask	Strong answer looks like
Zone mapping support	Can you review and comment on our EMP zone map?	Yes, with a documented review and written suggestions
Indicator selection	How do you choose indicator organisms for our category?	Category‑specific rationale citing recognized guidance
Trending and interpretation	Do you provide EMP trending outputs and reviews?	Portal trends plus scheduled review calls or reports
Positive finding response	What is your protocol for presumptive pathogen positives?	Written escalation steps and timelines shared upfront
Corrective action support	Can you help document investigations after exceedances?	Technical staff participate and provide written input
PCP documentation support	Can you provide method and design rationale in writing?	Standard deliverable, not an exception

If a lab struggles to address several of these areas, you are likely dealing with a transactional provider rather than a true partner, regardless of their per‑test price.

Communication and issue management

Communication quality shows up most clearly during problems. Ask yourself, over the last contract period:

Were you informed of presumptive positives promptly, by phone, before COAs were issued?
Did you hear about compromised samples or method changes proactively, or only once COAs raised questions?
How often did your team have to chase the lab for clarifications on confusing results?

Before renewing, review these patterns and treat them as performance data, not interpersonal complaints. They indicate how the lab behaves under stress, which is exactly when you need reliability.

Cost, Risk, and Total Value

Why price‑only decisions create hidden exposure

Lab selection driven mainly by unit price is one of the most common sources of avoidable risk. The apparent saving on the invoice often masks downstream costs caused by weak methods, out‑of‑scope tests, poor documentation, or slow turnaround.

A more realistic framing is not “cost per test,” but “expected cost of program failure where lab performance is a contributing factor.” This includes:

Recalls and market withdrawals triggered by questionable test data.
Regulatory findings tied to gaps in accreditation or method validation.
Production delays from missed turnaround windows.
Additional testing or investigations needed to resolve ambiguous results.

Once those costs are acknowledged, the cheapest lab rarely looks like the best choice.

Building a risk‑adjusted lab cost model

A simple risk‑adjusted cost model does not require advanced analytics. It requires categorizing your tests along two axes: regulatory significance and business impact.

Identify tests directly tied to regulatory verification, PCP requirements, or explicit safety claims.
Identify tests that gate release decisions and directly affect inventory, labor, and logistics.
Identify tests that are primarily exploratory, developmental, or low‑impact.

You can then map tests into a matrix such as:

Test Priority Matrix

Category	Regulatory significance	Production / commercial impact	Lab expectation
Pathogen verification on RTE	High	High	Highest‑capability, fully accredited lab
EMP pathogen screens	High	Medium	Accredited methods, strong EMP partnership
Shelf‑life indicators for labels	Medium	High	Accredited methods, solid documentation
Low‑risk EMP indicators, Zone 4	Low	Low	Some cost sensitivity acceptable
Exploratory R&D tests	Low	Low	Flexible, with clear separation from PCP data

This framework helps QA explain to finance and procurement why certain tests must sit with top‑tier labs, while others can be managed more aggressively on cost. In many plants, the outcome is not higher total spend, but better allocation, with more budget directed toward high‑impact validation and pathogen work and less on low‑risk routine tests.

Aligning with finance and procurement

Procurement involvement is not the problem; misaligned criteria are. Lab testing behaves poorly when treated like a commodity. To align, agree on two layers of criteria:

A non‑negotiable qualification floor, including ISO/IEC 17025 accreditation for your matrices, recognized methods, proficiency testing, and documented chain‑of‑custody and data governance.
A comparative layer for qualified labs, including price, service levels, portal capabilities, and value‑added technical support.

This gives procurement room to negotiate within a set of boundaries that protect your program. It also provides a clear, documented rationale for why some bids are excluded regardless of price, which is useful if decisions are reviewed in audits or governance forums.

Value of long‑term relationships

There is genuine value in a stable, long‑term relationship with a competent lab. Over time, they accumulate knowledge of your facility, processes, product mix, and historical trends. That knowledge makes their interpretation more useful and their support during incidents more precise.

For multi‑site manufacturers, standardizing on one or two strategic lab partners also improves data comparability across sites, simplifies training and documentation, and strengthens your position when negotiating pricing or service enhancements. Changing labs has a cost: onboarding, method harmonization, and a period of learning during which support may be weaker. That transition risk should be factored into renewal decisions alongside price and performance.

Contract Renewal Checklist for Canadian Food Manufacturers

Renewal as structured risk review

Renewal should function as a formal, documented review of performance, capability, and contract terms, not a courtesy signature. Ideally, QA leads this review 90 to 120 days before expiry, with input from operations and finance.

A practical three‑phase structure:

Lab Contract Renewal Framework

Review phase	Key questions	Documentation to collect
Phase 1: Performance	Did the lab meet turnaround commitments, particularly for holds?	Turnaround logs versus committed service levels
	Were there COA errors, method discrepancies, or scope issues?	Nonconformance and CAPA records
	How were positives and escalations handled?	Incident and communication logs
Phase 2: Capability	Is current scope aligned with your full test menu and matrices?	Current scope mapped to active tests
	Have products, processes, or markets changed since last renewal?	Product and market change summary
	Can the lab support upcoming validation or special studies?	Written confirmation from technical staff
Phase 3: Contract terms	Are service levels, rush rules, and escalation paths documented?	Draft or signed service agreement with SLAs
	Are data retention and portability clearly defined?	Data governance clauses or addenda
	Are pricing and annual adjustments explicit?	Signed fee schedule and adjustment rules

Completed properly, this review creates an audit‑ready record that shows you manage lab selection and oversight as part of your supplier qualification system, not as a purchasing habit.

Core items to verify before you sign again

Some items warrant review at every renewal, regardless of how the last term went.

Core Renewal Verification Checklist

Item	What to verify	Acceptable standard
Accreditation certificate	Valid ISO/IEC 17025 from SCC‑recognized body	Current, with no gaps in coverage
Scope document	All critical tests and matrices are within scope	Publicly verifiable scope matching your test list
Proficiency testing	Participation for key analytes with acceptable performance	Records available and reviewed
Method list	Methods used match recognized compendia	HPB, ISO, AOAC, or FDA BAM references documented
Nonconformance log	Recorded quality events and CAPA during contract term	Issues documented with closure evidence
Data retention policy	COAs and raw data retained for required duration	Aligns with your regulatory and shelf‑life needs
Escalation protocol	Written positive‑finding notification process	Client notified before COA release, with timelines
Technical contact	Named scientist or technical lead on your account	Direct, reliable contact details

If any of these cannot be provided in writing, that is a clear signal to pause before renewing.

Confirming scope against current products and markets

Scope and product portfolios both change. At each renewal:

Pull the latest scope and confirm that new products, reformulations, and export lines are covered for the relevant tests.
Pay attention to matrix distinctions, for example cooked versus raw, high‑acid versus low‑acid, or high‑fat versus low‑fat products.
For export‑driven programs, confirm that methods align with destination requirements and that the lab can provide documentation suitable for those regulators.

This is also the time to ask whether the lab plans any significant scope changes or method shifts in the next term and how those will be communicated.

Reviewing performance, nonconformances, and CAPA

Before meeting with the lab, compile:

Turnaround data for key sample types.
A list of any COA corrections, method queries, or disputes.
A summary of serious incidents or positive findings and how the lab supported your team.

Use this to ground the renewal conversation in facts. Labs that identify and correct their own issues and communicate transparently demonstrate a healthier quality culture than those that present a spotless record because nothing is ever documented.

When gaps emerge

The renewal review may surface gaps you cannot ignore. In that case, options include:

Negotiating documented remediation with timelines, such as scope expansion, improved escalation protocols, or additional technical support.
Adding a specialized partner for high‑risk or high‑complexity work while maintaining the current lab for lower‑risk routine tests.
Running parallel testing for critical analyses with another lab for a fixed period to compare performance and data quality before a full transition.

What matters is that you treat the gaps as explicit decisions, not as background noise.

Scenarios: How Different Plants Approach Lab Selection

Scenario 1: Mid‑sized RTE manufacturer moving beyond a regional lab

A mid‑sized ready‑to‑eat meat producer relied for years on a small regional lab. Pricing and turnaround were acceptable, and the relationship felt comfortable. During a GFSI recertification audit, the auditor requested the lab’s current scope and found that two pathogen methods used for RTE meat were not accredited for that matrix. The COAs did not clearly disclose this.

Faced with a finding and a short corrective action window, the manufacturer had two options: wait for the regional lab to expand scope, which would take several months, or move critical testing to a lab already accredited for the relevant methods and matrices. They chose to run parallel testing for eight weeks with a new ISO/IEC 17025 lab, then shift pathogen work once equivalence was demonstrated, while keeping the regional lab for low‑risk indicator tests.

The outcome was higher per‑test cost on the pathogen panel, offset by closing the audit finding, reducing regulatory exposure, and giving leadership a documented basis for budget changes anchored in risk rather than preference.

Scenario 2: Multi‑site processor consolidating to a strategic partner

A four‑plant processor had four different primary labs, each chosen locally at different times. When corporate QA tried to build cross‑site EMP trends, they discovered that method differences and reporting formats made results only loosely comparable. They also found that contract terms and service levels varied widely.

Corporate QA launched a formal RFP to several ISO/IEC 17025 labs capable of serving all locations. They weighted accreditation scope, method standardization, LIMS capabilities, technical support, logistics, and pricing. After selection, they standardized methods and COA formats across sites, implemented a single portal, and negotiated volume‑based pricing.

The main trade‑off was change management at site level. QA teams had to adapt to new contacts, processes, and report formats. Within a few months, the benefits of comparable data and reduced administrative burden outweighed the initial disruption.

Scenario 3: Export‑focused producer adding a specialized validation lab

A niche manufacturer of acidified specialty products had a long‑standing relationship with a competent accredited lab that handled EMP and finished product testing. When a major U.S. customer requested detailed kill‑step validation for acidification, the primary lab acknowledged that it did not design or run such studies.

Instead of replacing the routine lab, the manufacturer engaged a separate validation specialist with experience in acidified foods and FSMA process authority work. The specialist designed and executed challenge studies and produced documentation tailored to FDA expectations. The primary lab continued with routine testing, while both labs coordinated to ensure consistent methods where necessary.

This structure introduced some coordination overhead but allowed the manufacturer to meet export requirements without disrupting a stable routine testing relationship.

Frequently Asked Questions From Leadership

Does every test need to be ISO/IEC 17025 accredited?

Any test used for regulatory verification, PCP documentation, GFSI audits, or customer‑facing food safety evidence should be within an accredited scope for your matrices. For internal R&D, exploratory work, or low‑stakes benchmarking that will never appear in formal documentation, accreditation is less critical, provided those uses are clearly distinguished and not inadvertently presented as verification data.

The practical rule of thumb is simple. If a result might appear in an audit file, regulatory submission, or customer questionnaire, it is safer and more defensible to have that test within scope.

How do I confirm that a lab’s accreditation covers the tests and products I rely on?

Use the lab’s current scope document, not only their certificate. Retrieve it directly from the accreditation body or the SCC directory. For each test in your program, confirm:

The analyte matches what you are testing.
The method reference matches what appears on your COAs.
The matrix matches your product or class of products.

If you find a mismatch, ask the lab in writing whether that test is within scope for your products and request documentation. Keep the correspondence in your supplier qualification file.

What is a reasonable turnaround time for routine and rush testing?

For indicator organisms in typical food matrices, two to three business days from receipt to COA is a reasonable standard. For pathogen screens, three to five business days is common, with faster preliminary results when validated rapid methods are used. Rush services can shorten these windows, usually at premium pricing.

Rather than focusing on the nominal number of days, track how reliably the lab hits their commitments over time, especially for hold‑and‑release samples. Those patterns matter more than any single quoted figure.

Should my contract lab help design my EMP and investigations?

A technically capable contract lab should be able to support EMP design and corrective action work, while recognizing that ownership stays with your plant. At minimum, you can expect input on zone mapping, indicator organism selection, sampling frequency, and follow‑up strategies after exceedances.

Labs that decline to engage on EMP design or investigations, or can only offer generic advice, are unlikely to provide the level of partnership that complex RTE or high‑risk programs require.

How often should we review or retender our lab contracts?

A full structured review at each renewal is the minimum. In addition, an internal gap assessment every 18 to 24 months is useful, especially if you have launched new products, entered new markets, or undergone significant changes in process or capacity.

A formal RFP process makes sense when:

Significant capability gaps are identified and cannot be fixed within the current relationship.
Testing volume or program complexity has grown enough that a different level of partner is warranted.
Corporate strategy calls for consolidation or expansion into new geographies where current labs have limited reach.

How involved should executives be in selecting and overseeing lab partners?

Executives do not need to review method validation files, but they should:

Approve the selection and renewal criteria framework before QA and procurement begin evaluating options.
Review and sign off on renewal decisions, especially where cost, risk exposure, or capability changes are material.
Receive periodic summary reports on lab performance, including accreditation status, nonconformances, major incidents, and key service metrics.

This level of involvement keeps lab selection aligned with the organization’s risk appetite and strategic direction without dragging leadership into day‑to‑day operations.

Treating Your Lab as a Strategic Food Safety Asset

For QA and plant leaders, the most productive mindset shift is to treat the lab relationship as a core element of the food safety system, on par with HACCP, EMP design, and supplier approval, rather than a line item on the expense sheet. That mindset naturally leads to periodic, structured review; clear internal ownership; and a documented rationale for key decisions.

A practical internal next step is to commission a lab partner gap assessment that does not wait for renewal. Map your current lab’s scope to your test list, review the last year of COAs and communications, and ask your QA, operations, and finance leads where the relationship is supporting or straining the program. Capture these findings in a concise report, then use them to shape your next renewal or RFP.

If you want external support grounding these decisions in current regulatory and industry expectations, connect with a food microbiology partner that approaches testing as part of a larger, auditable system. Cremco Labs can help you review your current lab strategy, highlight gaps, and design a risk‑adjusted, compliance‑first approach to microbiology testing and validation. Reach out to discuss a structured assessment of your lab program and how a science‑driven, ISO 17025 accredited partner can support your Preventive Control Plan, EMP, and validation work across your current technology stack, process flow, and growth plans.